Neuriva is not FDA approved. It is classified as a dietary supplement, a category of products that does not require FDA approval before being sold to consumers. Under federal law, most dietary supplements can be brought to market without the FDA even knowing they exist.
Why Supplements Don’t Need FDA Approval
The Dietary Supplement Health and Education Act of 1994 (DSHEA) defines dietary supplements as a category of food, not drugs. That distinction matters because drugs must go through rigorous clinical trials and receive explicit FDA approval before reaching pharmacy shelves. Supplements skip that entire process. The companies that make and sell them are responsible for ensuring their own products are safe and that any label claims are truthful.
The FDA only steps in after a supplement is already on the market, typically if safety problems emerge or if a company makes illegal claims. Supplements are not permitted to claim they diagnose, treat, cure, or prevent any disease. They can make what are called “structure/function claims,” which describe how the product affects the body in general terms, like “supports brain health.” If you look at Neuriva’s label, you’ll find a disclaimer stating that the FDA has not evaluated these claims, which is legally required for any supplement making such statements.
What Neuriva Contains
The original Neuriva formula contains two active ingredients: 100 mg of whole coffee cherry extract and 100 mg of phosphatidylserine. Coffee cherry extract is the fruit surrounding the coffee bean, rich in plant compounds called polyphenols. Phosphatidylserine is a fatty molecule found naturally in brain cell membranes, where it plays a role in cell signaling and the protective coating around nerve fibers.
Neither ingredient is a novel compound. Coffee fruit extract received a “no questions” letter from the FDA through its Generally Recognized as Safe (GRAS) notification process, meaning the agency did not challenge the manufacturer’s own conclusion that it’s safe at levels between 20 and 300 mg per serving. That’s worth noting: a GRAS determination is not an FDA endorsement. It simply means the FDA reviewed the manufacturer’s safety data and didn’t object.
Phosphatidylserine has a slightly longer regulatory history. In 2003, the FDA allowed a qualified health claim stating that consumption of phosphatidylserine “may reduce the risk of dementia in the elderly.” But the agency required the claim to carry a disclaimer noting that the supporting research is “very limited and preliminary.” That qualified claim remains the strongest FDA-acknowledged statement about either ingredient.
What the Research Actually Shows
One published clinical trial tested the Neuriva formula specifically. It was a randomized, double-blind, placebo-controlled study in healthy adults who reported memory concerns. After 42 days of supplementation, the researchers reported improvements in memory, accuracy, focus, concentration, and learning compared to placebo. The study concluded the product was safe and well tolerated.
That sounds promising, but context matters. A review published in PMC noted that this trial was never registered on ClinicalTrials.gov, the federal database where researchers typically log study protocols before running them. Pre-registration is considered a basic standard of research transparency because it prevents researchers from selectively reporting only the outcomes that look favorable. A search of that database found no other registered protocols involving Neuriva. For a product sold in most major retailers and widely advertised on television, that’s a thin evidence base.
The broader research on the individual ingredients is mixed. Studies on phosphatidylserine and coffee cherry extract exist, but they vary widely in dosage, study population, and duration. Positive findings from small or short-term studies don’t automatically translate into reliable benefits for everyday consumers.
Legal Challenges Over Marketing Claims
Neuriva’s marketing has drawn legal scrutiny. A class action lawsuit alleged that manufacturer Reckitt Benckiser used false and misleading statements to give consumers the impression that Neuriva had been clinically tested and proven to improve brain function. The plaintiffs argued that while the advertising suggested the finished product had undergone rigorous testing, none of the actual Neuriva products had been tested in that way at the time.
A settlement was reached that prohibited Reckitt Benckiser from using phrases like “clinically proven,” “science proved,” or “clinically tested and shown” on Neuriva’s labeling. The company was still permitted to describe Neuriva’s ingredients as “clinically tested,” a narrower claim about the individual components rather than the finished product. The Eleventh Circuit Court of Appeals later vacated parts of the case on procedural grounds, but the settlement’s restrictions on marketing language had already taken effect.
What “Not FDA Approved” Means for You
The absence of FDA approval doesn’t automatically mean a product is unsafe or useless. It means the product has not undergone the level of testing the FDA requires for drugs, and no government agency has independently verified that it works as advertised. The safety and efficacy claims rest entirely on the manufacturer’s own evidence.
For Neuriva specifically, the ingredients have some preliminary research behind them, but the evidence is far from the standard required for a prescription or even an over-the-counter drug. The product is legal to sell, and its ingredients have established safety profiles at the doses used. What remains genuinely uncertain is whether taking it produces meaningful cognitive benefits beyond what you’d experience from a placebo. If you’re spending $30 to $50 a month on a brain supplement, that’s a question worth sitting with.